COMP <GO>
RMD vs BDX // EV/EBITDA & P/E VALUATION
ResMed Inc. (NYSE) VS. Becton Dickinson and Company (NYSE) • 15-METRIC TALLY: RMD 10
— BDX 4
▲ EV/EBITDA & P/E VALUATION LEADER: RMD
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
valuation
19.9x
LAST: $197.88 (-0.23%) • MKT CAP: $54.03B
valuation
21.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. BDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | BDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 45.40% | +14.00 | RMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.90% | 4.90% | +18.00 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.9x | 21.8x | -1.90 | RMD | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 2.13% | +2.54 | RMD | /fcf-yield <GO> |
| Operating Margin | 32.70% | 11.80% | +20.90 | RMD | /operating-margins <GO> |
| Net Profit Margin | 27.20% | 7.70% | +19.50 | RMD | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 8.20% | +1.60 | RMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 2.21% | -1.34 | BDX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.49 | 2.22 | +10.27 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | RMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.1 | 64.6 | -4.50 | BDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 1.06 | -0.13 | BDX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 29.9x | -6.30 | RMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $54.03B | -$18.47B | BDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | BDX REV | RMD GROSS % | BDX GROSS % | RMD FCF | BDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $21.84B | 59.4% | 45.4% | $1.66B | — |
| FY 2024 | $4.69B | $20.18B | 56.7% | 45.2% | $1.30B | — |
| FY 2023 | $4.22B | $19.37B | — | — | $503.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
BDX // BETA 1.06